Immune therapy of osteoarthritis: an open assessment of clinical results with heterologous antibodies to articular tissue ('Serocytol')

Pharmatherapeutica. 1986;4(9):577-84.

Abstract

Forty-three out-patients received treatment (6 months in 13 cases of spondylarthrosis, 12 months in 30 cases of gonarthrosis) with heterologous antibodies to articular tissue, given as 1 rectal suppository once every other day for periods of 4 weeks out of every 5. The treatment produced complete freedom from symptoms and signs of the illness in 5 (12%) patients and overall positive therapeutic results in 36 (84%), equally distributed in the disorders of the vertebral column and of the knee. This was accompanied by a significant improvement, both in terms of percentage improvement and the percentage of patients improved, of all monitored symptoms. The percentage improvement was similar for all components of the illness: pain, mobility and inflammatory-reactive component. No local or systemic side-reactions were recorded throughout the observation period, and there were no adverse effects on haematology, haematochemistry or renal function. A high percentage of patients reported a remarkable improvement in their quality of life, an overall measure of the therapeutic benefit-risk ratio as experienced by the individual patient.

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Immune Sera / administration & dosage*
  • Immunization, Passive
  • Joints / immunology*
  • Knee Joint*
  • Male
  • Middle Aged
  • Osteoarthritis / physiopathology
  • Osteoarthritis / therapy*
  • Spinal Diseases / therapy*

Substances

  • Immune Sera